Business Context and Reporting Period
Company: Disc Medicine, Inc. (Nasdaq: IRON)
Filing Type: Form 8-K (Current Report)
Date of Report: October 20, 2025
Event: Entry into a Material Definitive Agreement for an underwritten public offering of common stock and pre-funded warrants.
Key Financial Metrics and Offering Details
- Offering Price: $84.00 per share of Common Stock; $83.9999 per Pre-Funded Warrant.
- Shares Sold by Company: 2,619,049 shares of Common Stock.
- Pre-Funded Warrants Sold: 59,523 warrants (exercisable for Common Stock at $0.0001).
- Shares Sold by Selling Stockholder: 297,619 shares (AI DMI LLC).
- Over-Allotment Option: Underwriters exercised the full option to purchase an additional 446,428 shares from the Selling Stockholder on October 21, 2025.
- Net Proceeds to Company: Approximately $210.9 million (after underwriting discounts and estimated expenses).
- Proceeds to Selling Stockholder: Company receives no proceeds from the sale of shares by the Selling Stockholder.
- Liquidity Outlook: Management expects cash, cash equivalents, marketable securities, and net proceeds to fund operations into 2029.
Material Changes and Transaction Structure
This filing represents a significant capital raise event rather than a periodic financial performance report. The primary material change is the expansion of the company's cash reserves through the issuance of new equity. The transaction involves:
- Primary issuance of Common Stock and Pre-Funded Warrants by Disc Medicine, Inc.
- Secondary sale of existing shares by AI DMI LLC.
- Full exercise of the 30-day over-allotment option by underwriters.
- Closing of the Offering expected on October 22, 2025.
Guidance, Outlook, and Risks
Management Commentary: The Company anticipates that the net proceeds, combined with existing cash resources, will be sufficient to fund current operating and capital expenditure plans into 2029. This projection does not account for potential cash inflows from bitopertin or other marketed products if approved during that period.
Risks and Contingencies:
- Forward-Looking Statements: The filing contains forward-looking statements regarding the cash runway, which are subject to risks and uncertainties.
- Ownership Limits: Pre-Funded Warrants are subject to an ownership limit of 24.99% (or lower at holder election) to prevent change of control.
- HSR Thresholds: Exercise of warrants may be restricted if it triggers Hart-Scott-Rodino Antitrust Improvements Act filing requirements.
- Development Risks: Risks include the timing and cost of product development, clinical trial results, and regulatory approvals.
Investor Verification Checklist
- Verify the final closing date of the Offering (expected October 22, 2025) and actual net proceeds received.
- Confirm the updated share count and dilution impact following the issuance of Common Stock and Pre-Funded Warrants.
- Review the "Risk Factors" in the most recent Form 10-K and 10-Q for details on clinical trial timelines and regulatory hurdles.
- Monitor the exercise of Pre-Funded Warrants and any subsequent changes in beneficial ownership.
- Assess the company's burn rate against the stated 2029 cash runway projection.